Daiichi Sankyo

This study tests a new drug combination for people with extensive-stage small cell lung cancer, a fast-growing type of lung cancer. The treatment combines ifinatamab deruxtecan (I-DXd) with atezolizumab, with or without carboplatin, as a first treatment. About 123 adults will tak…

This early-stage trial tests a new drug called DS9051b in about 40 adults with advanced adrenocortical carcinoma or metastatic castration-resistant prostate cancer. The main goal is to check safety and find the right dose, while also looking for signs that the drug shrinks tumors…

This early-phase trial tests a new way to give the cancer drug trastuzumab deruxtecan (T-DXd) as a shot under the skin instead of through an IV. It includes about 76 adults with metastatic solid tumors that have spread. The main goals are to check safety, side effects, and the ri…

This study tests a new drug, datopotamab deruxtecan (Dato-DXd), combined with standard chemotherapy (carboplatin or cisplatin) in people with advanced bladder cancer that worsened after prior treatment with enfortumab vedotin and pembrolizumab. About 630 adults will be randomly a…

This study tests a new drug combination (Enhertu plus chemotherapy, with or without pembrolizumab) against the standard treatment for advanced HER2-positive stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 726 adults who have not received prior…

This study tests whether a targeted antibody-drug combo (trastuzumab deruxtecan) plus immunotherapy (pembrolizumab) works better than standard chemo plus immunotherapy for people with advanced non-small cell lung cancer that has high HER2 levels and low PD-L1. About 686 adults wh…

This early-stage trial tests whether adding valemetostat to the standard drug darolutamide is safe and tolerable for men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. About 60 adu…

This study tests whether adding the drug Dato-DXd to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced or metastatic non-small cell lung cancer that has high PD-L1 levels. About 740 adults with non-squamous lung cancer who hav…

This study tests two experimental drugs together in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 210 adults will take part in this early-phase trial.

This study tests whether adding valemetostat to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer that has high PD-L1 levels. About 137 adults who have not had prior treatment for advanced disease will take part. The goal is to see if …

This study will follow 800 Chinese adults with advanced HER2-positive or HER2-low breast cancer who are taking trastuzumab deruxtecan (T-DXd). Researchers will track how long the drug keeps the cancer from getting worse and note any side effects. The goal is to see how well the t…

This program offers access to an experimental drug called I-DXd for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments. It is for patients who have no suitable treatment options and cannot join a clinical trial. The goal is to …

This study tests two different doses of quizartinib as a maintenance therapy for adults with a specific type of acute myeloid leukemia (FLT3-ITD positive) who are in their first complete remission and have not had a stem cell transplant. The goal is to see which dose is safer and…

This study tests a new drug called DS-3939a in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the right dose, and to see if the drug can shrink tumors. About 540 adults will take part across multiple centers.

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. It is the first time this drug is being used in humans. The study has two parts: first, to find the safest dose, and second, to see how well…

This study tests a new drug called DS3790a in people with blood cancers like leukemia or lymphoma. The main goals are to check safety and see if the drug can shrink tumors. About 420 adults will take part, and the drug is given alone or with other treatments.

This study tests whether adding trastuzumab deruxtecan (T-DXd) to standard bevacizumab maintenance therapy helps women with advanced HER2-expressing ovarian cancer live longer without their cancer growing. About 582 participants will receive either the combination or bevacizumab …

This study tests whether adding the drug quizartinib to standard chemotherapy helps adults with a specific type of acute myeloid leukemia (AML) live longer. About 700 adults aged 18 to 70 with newly diagnosed FLT3-ITD negative AML will receive either quizartinib or a placebo alon…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in 250 people with advanced breast cancer that has low or no HER2 protein. The goal is to see how long the drug can control the cancer before another treatment is needed. Participants must have cancer that cannot be re…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The trial includes 740 participants with 13 different cancer types, such as lung, breast, and prostate cancer. The goal is to see if the …

This early-stage trial tests a new drug called DS3610a in 70 adults with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. This is a first-in-human study, so it focuses o…

This study gives people with advanced or metastatic cancer continued access to experimental drugs they are already benefiting from in earlier studies. The main goal is to monitor long-term safety, including side effects. About 50 participants will join this Phase 3 rollover study…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people with advanced or metastatic solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow disease progression. About 200 adults will take part, and the…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with advanced esophageal cancer that has worsened after standard chemotherapy and immunotherapy. About 510 adults will be randomly assigned to receive either I-DXd or a standard chemotherapy chosen by thei…

This study tests an experimental drug called ifinatamab deruxtecan (I-DXd) in people whose cancer has come back or spread. It includes 13 different cancer types, such as endometrial, head and neck, pancreatic, and breast cancers. The goal is to see if the drug can shrink tumors a…

This study is testing a new drug called R-DXd in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy. The drug works like a guided missile, targeting a protein on cancer cells to deliver a powerful toxin. The trial will measu…

This study tests a new drug, ifinatamab deruxtecan, against standard treatments for people whose small cell lung cancer has returned. About 540 adults with advanced disease will be randomly assigned to receive the new drug or a doctor-chosen therapy. The goal is to see if the new…

This early-stage trial tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This phase 3 trial tests whether the targeted drug trastuzumab deruxtecan (T-DXd) works better than standard chemotherapy (with or without radiation) to prevent endometrial cancer from coming back after surgery. The study enrolls 710 adults with HER2-expressing endometrial cancer…

This study looks at the long-term risk of severe liver damage in people with a type of tumor called TGCT who have taken the drug TURALIO (pexidartinib) and already had liver test problems. Researchers will track about 30 adults to see how often liver failure occurs after stopping…

This study looks at how the drug quizartinib is processed in people with severe liver problems compared to healthy people. About 12 adults will receive a single dose, and researchers will measure drug levels and side effects. The goal is to understand how liver impairment affects…